TB-500 and BPC-157 peptide claims: what the science says

What did @biomaxelite actually say?

The video presents itself as an educational explainer, with the creator speaking as the peptide itself. The core claims: Tessa Moralin (tesamorelin) works through GHRH receptor activation, stimulates a precise GH pulse that "specifically targets visceral adipose tissue," and that "clinical trials demonstrated significant reductions in visceral fat volume" measurable "within weeks." They also claim improvements in lipid profiles and insulin sensitivity. That framing, a peptide narrating its own mechanism in first person, is designed to sound authoritative while sidestepping accountability.

The hashtags "researchpurposesonly" and "educationalpurposesonly" are doing a lot of legal heavy lifting here. That framing does not change the real-world effect of presenting clinical outcome claims to a general audience who may not know what tesamorelin is actually approved for, or what population the trials enrolled.

Does the science back this up?

Partially, yes, but the context is everything, and the video strips it away. Tesamorelin is a synthetic GHRH analog with genuine clinical trial data, mostly in people living with HIV-associated lipodystrophy. The GH pulse mechanism is real. The visceral fat reduction is real in that population. Outside of it, the evidence is thinner.

The FDA approved tesamorelin (Egrifta) in 2010 specifically for HIV-associated lipodystrophy after trials showing roughly 15-18% reductions in visceral adipose tissue (VAT) measured by CT scan (Falutz et al., 2010, New England Journal of Medicine). A follow-up 52-week trial confirmed durability (Falutz et al., 2008, NEJM). Lipid profile changes were observed, including modest reductions in triglycerides. Insulin sensitivity data from those trials was more mixed than the video implies. The claim that trials show improvements in insulin sensitivity is an oversimplification at best.

What did they get wrong (or right)?

Credit where it is due: the GHRH receptor mechanism is accurately described. Tesamorelin does bind GHRH receptors, does stimulate pulsatile GH release, and the downstream lipolytic effect on visceral fat is pharmacologically real. That is not pseudoscience.

But "specifically targets visceral adipose tissue" is an overstatement. GH-driven lipolysis is preferential toward visceral fat, not exclusive to it. Subcutaneous fat can also be affected. More importantly, the video says nothing about the fact that VAT reduction largely reverses within 12 weeks of stopping treatment (Falutz et al., 2010). There is no mention that the clinical data comes almost entirely from people with HIV-associated lipodystrophy, not general obesity populations. Applying these results to a general fitness or optimization audience is a significant leap the evidence does not support. "The precision of this research is unmatched" is marketing language, not a scientific finding.

What should you actually know?

Tesamorelin is a real, FDA-approved peptide with a legitimate clinical record in a specific population. It is not a general-purpose fat loss drug, and the trial data does not translate cleanly to healthy adults seeking body composition improvement. The video presents cherry-picked outcomes from a narrow patient population as if they apply universally.

There are also real risks the video ignores entirely: glucose metabolism effects including elevated fasting glucose and insulin resistance in some users (Falutz et al., 2010), fluid retention, arthralgias, and the need for ongoing monitoring. Tesamorelin is not approved for general weight loss or sports optimization. Compounded versions circulating in the peptide market are not equivalent to FDA-approved Egrifta and carry their own regulatory and safety considerations. Anyone considering this peptide should be working with a licensed clinician who has reviewed their full metabolic panel, not making decisions based on a TikTok video narrated in first person by the drug itself.